KAIFENG, China, Aug. 21, 2025 /PRNewswire/ — Recently, JETOUR Auto held its 8th global Fan Festival in the historic city of Kaifeng under the theme “Travel Worldwide.” Over 1,000 fans from around the world gathered to participate in the co-creation of JETOUR’s first premium off-road SUV, the G700, and witnessed the official launch of”Worldwide Children’s Welfare.” The event reflected the brand’s commitment to user co-creation and global social responsibility.

During the festival, users were invited to visit JETOUR’s Kaifeng Intelligent Manufacturing Plant. By closely observing the advanced production lines and strict quality control systems, attendees gained a deeper insight into JETOUR’s technical expertise, which reinforced trust in the brand’s commitment to quality.

In line with its”Travel Worldwide”vision, JETOUR International launched the “Worldwide Children’s Welfare” during the fan festival. The initiative has already been rolled out in South Africa, Iraq and Angola. The project, through activities such as school supply donations and traffic safety education, offers tangible care and support to children in need. At the event, JETOUR also presented the “CSR Contribution Award” to eight users for their outstanding contributions to charitable causes.

A highlight of the festival was the G700 Co-Creation Workshop, a special segment where users were invited to share ideas on vehicle features, optimizations, and real-life usage scenarios. Their enthusiastic input provided valuable feedback for the G700. As JETOUR’s first premium off-road SUV, the G700 reflects the brand’s “user-oriented” development philosophy—empowering users to shape the future of travel together.

From global charity initiatives to intelligent manufacturing tours and product co-creation, the 8th global Fan Festival embodied JETOUR’s brand values. Through charity, technology, and culture, JETOUR continues to strengthen its “Travel⁺” identity and evolve into a truly “user-oriented” brand.

HONG KONG, Aug. 21, 2025 /PRNewswire/ — BIEL Crystal, a key Apple supplier and global leader in smart device components, has launched its revolutionary ultra-hard coating smartphone glass cover – “Witch Cloak”. This breakthrough cover glass is now featured on Honor’s latest Magic V5 foldable smartphone.

According to official Honor mobile phone data, devices equipped with Witch Cloak glass demonstrate:

10x improvement in drop resistance

15x enhancement in scratch prevention

3x increase in abrasion durability

significantly reducing screen cracks and breakages from everyday impacts.

About WITCH CLOAK ultra-hard coating

The Witch Cloak ultra-hard coating glass utilizes a glass-ceramic substrate coated with precisely alternating layers of silicon nitride (SiN) and silicon oxynitride (SiON). BIEL Crystal offers customizable coating solutions ranging multilayer to meet specific durability requirements.

About BIEL Crystal

Founded in 1989, BIEL Crystal is a leading global provider of exterior structure and module solutions for smart devices. Our products are widely used in smart digital devices, smart wearable devices, AR/VR glasses and automotive industry. Our long-term cooperation customers include Apple, Samsung, Xiaomi, vivo, Meta, ByteDance, Tesla, Google and so on.

With more than 30 years of technological innovation and excellent management, BIEL Crystal has become a large technology innovation group with 9 advanced production bases worldwide, with a total investment of over HK$42 billion, covering a total area of about 4.3 million square meters, employing more than 90,000 people and with an annual production capacity of 2.2 billion pieces.

-Your perfect shopping getaway just outside the city

SEOUL, South Korea, Aug. 21, 2025 /PRNewswire/ — In 2025, marking its 20th anniversary, Shinsegae Simon declared the beginning of the “Premium Outlet 2.0” era, signaling a new turning point in Korea’s outlet industry.

To enhance the shopping experience for international visitors, Shinsegae Simon is upgrading its infrastructure by introducing global payment systems, expanding exclusive promotions for foreign tourists, and operating multilingual websites. Additionally, the company has rebranded its online mall recently to create a seamless omnichannel shopping environment, offering travelers to Korea a more convenient and enriching retail experience.

As Korea continues to attract “K-culture lovers” from around the world, Shinsegae Simon Premium Outlets have become a must-visit destination for those seeking both shopping and relaxation. With locations near Seoul and in key tourist cities like Busan and Jeju, Shinsegae Simon Premium Outlets are strategically positioned for easy access and memorable shopping.

Shinsegae Simon operates premium outlet centers in Yeoju, Paju, Siheung, Busan, and Jeju, offering convenient access and a curated mix of luxury and local brands in a scenic, open-air setting. Popular among Koreans as a weekend getaway destination, Shinsegae Simon Premium Outlets offer a glimpse into everyday Korean leisure culture. For those looking to experience how locals spend their weekends, a visit to the outlets comes highly recommended.

Among them, Yeoju Premium Outlets stands out as Korea’s most prestigious premium designer outlet. Operated by Shinsegae Simon—a joint venture between Korean retail conglomerate Shinsegae and Simon Property, the leading outlet operator in the United States—Yeoju Premium Outlets offers an unparalleled selection of global luxury brands and Korean fashion labels.

Recognized by Forbes as one of the world’s top 10 outlet centers, Yeoju Premium Outlets features over 270 renowned brands including Burberry, Gucci, Prada, Bottega Veneta, Fendi, Ferragamo, and Moncler with year-round discounts ranging up to 65%. The outlet also showcases exclusive brands such as Wooyoungmi, Acne Studios, Recto, Lululemon, and Loro Piana, along with international beauty products offered at highly competitive prices. The open-air layout, divided into East and West zones, allows visitors to enjoy a scenic shopping experience, complemented by a variety of dining options including premium food court.

Traveling to Yeoju Premium Outlets is easy and convenient. A direct express bus from Seoul’s Gangnam Express Bus Terminal takes approximately one hour. Additionally, one-day bus tour packages were newly launched this year, departing from popular tourist areas such as Myeongdong and Hongdae. These packages include round-trip transportation and ample time for shopping and leisure at the outlet. Tickets can be booked through global OTA platforms including HanaTour ITC, KLOOK, and KKDAY, making it easier than ever for travelers staying in both southern and northern parts of Seoul to visit.

Likewise, Jeju Island-renowned for its breathtaking natural landscapes and status as one of Korea’s top tourist destinations-is home to Shinsegae Simon Jeju Premium Center, located within the Shinhwa World Resort complex in Seogwipo. The shopping center offers a fully indoor shopping experience—ideal for Jeju’s unpredictable weather—and is just an hour from Jeju International Airport by car or direct bus. In June 2025, the center welcomed the opening of a new Polo Ralph Lauren store-the brand’s first directly operated outlet in Jeju-further enhancing its appeal to international visitors. Featuring over 60 brands including Moncler, Coach, and Tod’s, the shopping center also provides on-site tax refund services and a comfortable, climate-controlled environment, making it a convenient and stylish destination for both tourists and locals.

For travelers using Seoul/Incheon International Airport, Siheung Premium Outlet is a highly recommended stop. Conveniently located between Seoul and Incheon, it’s just a 30-minute drive from the airport, making it an ideal destination for shopping before departure. In April 2025, the outlet underwent a major renewal with the opening of its new indoor shopping zone, The S Mall, featuring popular lifestyle brands such as Olive Young, Daiso, and Musinsa Standard. This well-curated selection allows international travelers to easily experience Korean beauty, daily essentials, and trendy fashion in a single stop.

To enhance the shopping experience for international visitors, Shinsegae Simon continues to invest in infrastructure and services tailored to the needs of Free Independent Travelers (FIT). Since last year, the outlets have supported global mobile payment systems such as WeChat Pay, Alipay, and LINE Pay Taiwan, ensuring seamless and secure transactions for international visitors. Exclusive discount coupons for foreign customers are available through the ‘E-COUPON’ program, and a special LINE Pay Taiwan promotion currently offers up to 30% cashback. Tax refunds can also be processed on-site, providing a convenient one-stop shopping experience.

Throughout the year, Shinsegae Simon Premium Outlets host a variety of pop-up stores and seasonal events, adding to the dynamic atmosphere and appeal for international tourists.

“We are committed to enhancing infrastructure and services so that international visitors can enjoy a more convenient and rewarding shopping experience at our outlets. We invite travelers to discover the unique brand offerings, comfortable facilities, and generous benefits that await at Shinsegae Simon Premium Outlets during their journey in Korea.” said a Shinsegae Simon official.

SINGAPORE, Aug. 21, 2025 /PRNewswire/ — The Management Development Institute of Singapore (MDIS) will be hosting a fireside chat titled “Part-Time, Full Impact: A Conversation on Work, Life, and Part-Time Studies” on 30 August 2025. This fireside chat is designed to offer working professionals practical insights into balancing part-time studies with full-time work and personal responsibilities.

Insights From Those Who’ve Done It

As more mid-career professionals in Singapore seek to stay relevant in a changing job market, flexible and skills-based learning options have become increasingly important. However, many adult learners still face significant challenges, such as managing time between work, family, and studies, as well as overcoming self-doubt.

This upcoming chat will bring together MDIS alumni and faculty members who have either experienced or supported such learning journeys. Panellists include:

• Max Eng, alumnus of the Bachelor of Arts (Hons) Airline and Airport Management (Top-up), from Teesside University, UK
• Karice Choo, alumna of the Bachelor of Arts (Hons) Business and Management (Top-up), from the University of Sunderland, UK
• Qamarzeb Aurangzeb, Programme Manager (Tourism and Hospitality), from MDIS

Together, they will share personal insights into managing these common struggles. The fireside chat will also cover career transition stories and strategies for returning to school after time away, with practical tips on time management, staying motivated, and adapting to academic expectations.

Flexible Options for Working Professionals

The upcoming event will also highlight how MDIS’s part-time degree programmes are structured to help support not just academic growth but also career development. Designed with working adults in mind, these courses align with industry needs and allow learners to apply their skills directly in the workplace.

Alongside the fireside chat, MDIS is also offering ongoing benefits for participants who sign up for selected MDIS part-time degree courses in Singapore. This includes scholarship grants as well as a voucher giveaway, further supporting applications’ transition back into education.

Those interested in attending the event or exploring flexible education options can visit www.mdis.edu.sg/part-time-full-impact-fireside-chat-lp for more information and registration details.

About MDIS

The Management Development Institute of Singapore (MDIS), established in 1956, is a private education institution (PEI) that offers preparatory courses, diplomas, and degree programmes in partnership with universities from the United Kingdom and the United States. As a not-for-profit professional institute, MDIS provides academic pathways in various disciplines, with options available for both full-time students and working adults seeking part-time study.

SHANGHAI, Aug. 21, 2025 /PRNewswire/ — From August 20 to 22, 2025, the Assembly Character Toys brand Blokees made its debut at the 2025 Indonesia International Toys Expo. Blokees exhibited over 50 model kits that are based on world-renowned IPs such as Ultraman, Transformers, Naruto, Minions, and Hero Infinity. In addition, nearly ten new model kits made their global debut on display.

With its rich and diverse product lineup, Blokees effectively meets the needs of players across a wide range of age groups and preferences. The booth attracted substantial interest from distributors and quickly became one of the highlights of the entire event.

Blokees’ new product was filled with highlights. Its Minions Mokoo Series 02: Summer Bello made its world debut at the exhibition, featuring six characters that embody the essence of a summer atmosphere. Stuart and Phil are depicted holding ukuleles, while Bob and Carl sport swimming rings. Kevin and Dave, transformed into tourists, are dressed in sunglasses, beach shorts, garlands, and water cups—offering an unexpected delight to devoted Minions fans.

Blokees’ Transformer Defender Version Series Devastator became the focus of the event due to its innovation. As the first combiner character in the history of the Transformers IP, the Blokees’ R&D team, through multiple rounds of optimization, faithfully captured the character form of Devastator. Players only need to collect all six Digger Team vehicle products from the Blokees’ Transformer Defender Version Series 01, 02, and 03 to exchange for the “Devastator Pack” and easily achieve Devastator. Behind this innovation is Blokees’ robust R&D system, supported by over 500 patents, underscoring the brand’s strong innovation capabilities and core competitive edge.

In addition to its diverse product lineup, Blokees is enhancing regional engagement through BFC culture. At the exhibition, Blokees exhibited BFC works from Indonesian BFC creators, demonstrating a profound co-creation between the brand and its users.

Through its “Universally appealing；Stepwise pricing；Globally promoting” strategy, Blokees has achieved significant breakthroughs in multiple international markets, including Southeast Asia, Europe, North America, and Latin America. Blokees is promoting Chinese Assembly Character Toys onto the global stage.

— Advancing a Sustainable Manufacturing Business Model —

KAWASAKI, Japan and TOKYO, Aug. 21, 2025 /PRNewswire/ — Toshiba Corporation and battery-tech startup naturenix inc. are taking their battery subscription demonstration test for electric motorcycle taxis in Bangkok, Thailand, to the next level by expanding the scale and shifting to a paid subscription model. Both companies are now preparing for the transition, and production of battery packs and related components has started. The new phase will run from December 2025 through March 2026.

From September 2024 to March 2025, the two companies conducted the first phase of service testing free of charge, allowing motorcycle taxi drivers to quickly swap battery packs at a dedicated charging station and return to carrying passengers^*1. In this trial, Toshiba supplied its SCiB™ lithium-ion batteries, while naturenix developed battery packs and chargers and modified the motorcycles. Sensors embedded in the motorcycles collected data on ambient temperature, environmental conditions, and driver behavior. The results, alongside driver surveys, confirmed the long-life and reliable performance of SCiB™, even in the torrid heat of Bangkok, and validated naturenix’s core technologies.

The paid service will be larger in scale, supporting up to 100 electric motorcycles, and one charging station will become five, covering Bangkok and its environs. Toshiba will continue to supply SCiB™ batteries, and naturenix will provide its proprietary system, a solution for rapid charging with standard power outlets. To refine the service, the two companies will leverage Thailand’s Windee International^*2 to gather feedback from drivers, including their reactions on pricing. They will also identify technical challenges resulting from scaling up production, evaluate the performance of the new charging technology, and analyze battery degradation while exploring potential countermeasures.

The battery packs for the second round of testing are upgraded and improved, with real-time monitoring of usage history and cell-level degradation, coordinated control across multiple packs, and optimized management for rapid charge/discharge cycles. Designed for reuse and repurposing in second-life applications, the new packs will contribute to development of a circular electrification ecosystem that maximizes resource use and reduces disposal-based recycling.

Toshiba and naturenix position the service as the proving ground for a new business model. In response to growing environmental concerns and the resource depletion associated with mass production and consumption, the two companies are advancing a sustainable business model centered on long-life batteries and subscription-based services. This approach challenges the traditional “volume equals revenue” paradigm by prioritizing durability over disposability, and aims to realize a more sustainable manufacturing framework.

Following the second round of demonstration testing, Toshiba and naturenix plan to launch a commercial subscription service for motorcycle taxi drivers in fiscal year 2026, and look to future expansion into industrial applications such as forklift trucks. Over the long term, Toshiba and naturenix will advance the integration of mobility and energy infrastructure as a unified service, aiming to expand both its applications and business scope.

^*1 Toshiba and Naturenix Launch Demonstration Test of Battery Subscription Service for Electric Motorcycle Taxis in Bangkok

^*2 naturenix’s joint venture with a local parking management service provider.

About Toshiba

In 2025, the Toshiba Group celebrates its 150th anniversary. As the company looks ahead, it is enhancing its management structure, streamlining operations, and investing in forward-looking businesses to build foundations for new growth. This will allow it to continue to support advances toward a sustainable future with products and services developed by its wide range of businesses in the energy, infrastructure, and electronic devices domains.

Guided by its corporate philosophy, “Committed to People, Committed to the Future.,” Toshiba brings industry-leading capabilities in green transformation (GX) and digital transformation (DX) to solutions for companies addressing the many challenges faced by modern society. By leveraging the power of data derived from its constantly evolving products and solutions, the Group is determined to help to achieve carbon neutrality and a circular economy.

In fiscal year 2024, Toshiba Group recorded annual sales of 3.5 trillion yen and employed 95,000 people worldwide. For more information, visit our website or follow us on LinkedIn.

About naturenix

naturenix is a start-up company that aims to create a world where nature and electronics coexist through the provision of battery longevity technologies and next-generation energy platforms. By collecting dynamic data on batteries in actual use and analyzing it with AI technology, the company promotes open innovation in batteries and ensures long-term use across multiple applications by guaranteeing asset value based on an understanding of battery use and degradation. For more information, please visit https://www.naturenix.co.jp/en/index.html

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.

H1 2025 key results^[1]

Group performance^[2]: Reflects strategic investment for long-term value creation

• Revenue of $390.4 million, up by 63%^[3] and on track to meet full year guidance^[4].
• Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable.
• Adjusted EBITDA^[5] of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and research and development (R&D) investment.
• $81.6 million invested into R&D, a 47% increase year-over-year. Investment was primarily focused on late-stage assets in the therapeutics and precision medicine pipeline. Full year R&D investment guidance is maintained^[6].
• Loss before tax of $4.8 million includes $12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024 and increased amortization cost of $9.5 million (2024 $2.4 million) following RLS acquisition.
• Positive operating net cash flow of $17.7 million, cash balance $207.2 million following $241. 8 million of strategic merger and acquisition (M&A) investment.

Telix Precision Medicine: Commercial business delivers profitable growth

• Precision Medicine segment revenue up by 30% compared to H1 2024, driven by continued increase in Illuccix dose volumes.
• Illuccix gross margin remains stable at 64%.
• Adjusted EBITDA up by 24% year-over-year to $104.6 million.
• Selling and marketing expenses of $40.9 million, reflecting incremental investment in commercial infrastructure for new product launches (Illuccix European launches and Gozellix®, Zircaix® and Pixclara®^[7]).

Telix Manufacturing Solutions (TMS): Investment in infrastructure to scale operations and meet future demand

• TMS segment includes RLS Radiopharmacies (RLS, U.S.^[8]), IsoTherapeutics (TX, U.S.), and TMS facilities in Sacramento (CA, U.S.), Brussels South (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly augmented global production and manufacturing footprint to support clinical and commercial operations.
• Operating expenses of $30.5 million for the segment include $14.9 million for RLS business and $15.6 million to support start-up and integration activities (ex-RLS).
• RLS – the core revenue driver in TMS – reported $109.5 million of revenue, which includes $79.0 million from third-party PET^[9] and SPECT^[10] product sales and distribution service fees, and $30.5 million inter-segment revenue.
• RLS delivered an Adjusted EBITDA loss of $1.1 million.
• RLS operating loss includes $6.3 million of depreciation and amortization.

Telix Therapeutics: Reinvesting earnings to accelerate late-stage pipeline

Of the total R&D investment, 54% ($43.9 million) was invested in the therapeutics pipeline. Milestones achieved include:

• TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan): Completed target enrollment of 30 patients for Part 1 of the Phase 3 study in advanced metastatic castration resistant prostate cancer (mCRPC). The trial has received regulatory approval to proceed in Australia, China, Canada, New Zealand, Turkey and Japan.
• TLX592 (²²⁵Ac-PSMA-RADmAb): Approval to commence a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced mCRPC.
• TLX101 (¹³¹I-iodofalan, or ¹³¹I-IPA): Approval to commence IPAX BrIGHT, an international pivotal trial, to commence at Australian sites initially.
• TLX090 (¹⁵³Sm-DOTMP): Investigational New Drug (IND) application approved for a Phase 1 bridging study for Telix’s therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone.

Commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the result:

“Telix continues to deliver strong revenue growth while building a foundation for the future. The first half of 2025 was a period of rapid transformation as we expanded our global manufacturing operations, invested in launching new products in new markets, and accelerated the development of our therapeutic pipeline. These investments have positioned Telix for sustainable, long-term growth, while our diversified business provides multiple drivers of success. To generate future revenue growth, we are confident in securing product approvals for Pixclara and Zircaix while advancing geographic and indication expansion for the PSMA portfolio.”

Summary Group financial results

Guidance

• Telix confirms FY 2025 revenue guidance of US$770 million to US$800 million^[11].
• Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS^[12].
• Telix confirms R&D expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024.

lnvestor call

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).

Participants can register for the webcast by clicking here: https://edge.media-server.com/mmc/p/x4gytx8w/ or the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)
Ms. Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country.

Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

[1]. See summary Group financial results table at end of this document.
[2]. Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).
[3]. All comparisons to H1 2024 results.
[4]. FY 2025 revenue guidance of US$770 million to US$800 million.
[5]. Earnings before interest, tax, depreciation and amortization.
[6]. Increased investment range for FY 2025 expected to be 20% to 25% compared to FY 2024.
[7]. Launch and brand names subject to final regulatory approval.
[8]. RLS network is comprised of 28 locations across the U.S.
[9]. Positron emission tomography.
[10]. Single photon emission computed tomography.
[11]. Refer to ASX disclosures 20 February 2025.
[12]. See Guidance Disclaimer for further information.